Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Lepu Biopharma Co. Ltd. Class H ( (HK:2157) ) has provided an update.
Lepu Biopharma Co. Ltd. has successfully completed the placing of 93,825,000 new H shares, raising approximately HK$462.94 million in net proceeds. The funds will be allocated towards the commercialization and marketing of MRG003, advancing clinical trials of core products, and research and development of new product pipelines. This strategic move increases the company’s total issued shares and strengthens its financial position to enhance its market presence in the oncology sector.
More about Lepu Biopharma Co. Ltd. Class H
Lepu Biopharma Co. Ltd. is a pharmaceutical company based in China, focusing on the development and commercialization of oncology drugs. The company is engaged in advancing clinical trials and research and development of new product pipelines, with a particular emphasis on its core product, MRG003 (EGFR-ADC).
Average Trading Volume: 19,800,911
Technical Sentiment Signal: Buy
Current Market Cap: HK$8.55B
See more data about 2157 stock on TipRanks’ Stock Analysis page.